Connect with us

Health

EMA recommends eight new medicines for approval

SHARE:

Published

1 month ago

on

We use your sign-up to provide content in ways you've consented to and to improve our understanding of you. You can unsubscribe at any time.

The European Medicines Agency’s Committee for Medicinal Products for Human recommends eight new medicines for approval, alongside 13 extensions of indication for existing medicines.

Among the headline recommendations at EMA’s Committee for Medicinal Products for Human Use (CHMP) meeting were three new treatments and one orphan medicine.

Lung fibrosis
Jascayd (nerandomilast), from Boehringer Ingelheim, for the treatment of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) received a positive opinion IPF and PPF affects more than 500,000 people across the EU.

“Current treatments for IPF and PPF, including in patients whose PPF is associated with underlying...

Share this article:

Share this:
Related Topics:
Guest Contributor - Opinion

Opinions expressed are purely those of the author and not endorsed by EU Reporter. The article was unsolicited by EU Reporter, and the author guarantees the truthfulness of the contents of the article. No payment was made by EU Reporter to the author

EU Reporter publishes articles from a variety of outside sources which express a wide range of viewpoints. The positions taken in these articles are not necessarily those of EU Reporter. Please see EU Reporter’s full Terms and Conditions of publication for more information EU Reporter embraces artificial intelligence as a tool to enhance journalistic quality, efficiency, and accessibility, while maintaining strict human editorial oversight, ethical standards, and transparency in all AI-assisted content. Please see EU Reporter’s full A.I. Policy for more information.
Advertisement

Trending